[Music] Good morning everyone or I think it's good afternoon. Yeah. So good afternoon everyone.Thank you all for being here. I am actually today going to take you on a journey. So a journey which is emotional roller coaster, a journey which is part therapy session and a journey which is part stand-up comedy.Why. Because life is too short to be serious at all times. Even when we are speaking about subjects as heavy as child sexual abuse.Today I am here to share my story. A story of pain, a story of resilienc ...

Otsuka’s medicine for PTSD with partner Lundbeck failed to win the backing of US regulatory advisers, a major setback in the drugmakers’ bid to bring the first new drug for the condition to market in more than two decades https://t.co/rR0B7sLNgG ...

[Music] You are not crazy. Well, let's start by saying that this is a life. Maybe not completely, but at least partially.And for that, I would talk about myself in the beginning. Sometimes I question if I'm crazy. More like I always question if I'm crazy.The reasons deferred over time. I used to question if I'm crazy because I fear mannequins. Then I started to question if I'm crazy because I'm scared of aliens abducting me, putting me in a small room where I suffocate when no one noticing or because I just ...

Core Points - A tragic plane crash involving a Boeing 787 occurred shortly after takeoff from Ahmedabad Airport, resulting in the deaths of 265 individuals, including 241 passengers and at least 24 ground staff [2] - This incident marks the first fatal accident for the Boeing 787 in its 14 years of service and is one of the deadliest aviation disasters since the 2014 Malaysia Airlines incident [2] Group 1: Survivor Stories - Bomi Choksi, a passenger who missed the flight due to a traffic jam, reflects on her narrow escape from the disaster, realizing that her delay saved her life [4] - Vishwashkumar Ramesh, the only surviving passenger, describes the chaotic moments during the crash and his miraculous escape through an unexpectedly opened emergency exit [8] - Both survivors face significant psychological burdens, with Ramesh grappling with survivor's guilt after losing his brother in the crash, while Choksi experiences feelings of "survivor's guilt" for outliving others [11] Group 2: Reflections on Fate and Life - The ongoing investigation into the crash will determine the cause, whether mechanical failure, bird strike, or human error, highlighting the unpredictability of fate [14] - The experiences of the survivors underscore the fragility of life and the importance of cherishing every moment, as their survival was influenced by a series of random events [14]

SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17/954,858 (titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders”) that Silo licenses from Columbia University. The to ...

Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7 ...

COMPASS Pathways (CMPS) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Steve Schultz - Senior Vice President, Investor RelationsKabir Nath - Chief Executive OfficerTeri Loxam - CFO, Principal Financial Officer & Principal Accounting OfficerGuy Goodwin - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchCharles Duncan - Managing DirectorSteve Levine - Chief Patient OfficerSumant Kulkarni - Managing DirectorPatrick Trucchio - Managing Director Conference ...

Financial Data and Key Metrics Changes - As of March, the company had cash and cash equivalents of $260 million, an increase from $165 million at the end of 2024, indicating a strong financial position following recent financing [12] - Cash used in operations for the first quarter was $45.7 million, with an expected net cash usage for the full year 2025 projected to be between $120 million to $145 million [13] Business Line Data and Key Metrics Changes - The company announced the completion of dosing for all participants in Part A of its pivotal Phase III trial for treatment-resistant depression (TRD), with top-line results expected in late June [5] - The Phase III program aims to confirm the durability and safety profile of COMM360, which could provide a groundbreaking treatment option for TRD patients if successful [9] Market Data and Key Metrics Changes - The company is focusing on the commercialization of COMM360 by developing relationships with various provider types through strategic collaborations, including a new partnership with HealthPort to enhance access to innovative mental health treatments [10] Company Strategy and Development Direction - The company is preparing for the commercialization of COMM360 by understanding the commercial opportunity and ensuring broad delivery across various care settings [9] - The strategic collaboration with HealthPort aims to address the needs of underserved populations, reflecting the company's commitment to equitable access to mental health treatments [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Phase III data readout, emphasizing the potential of COMM360 to be a clinically differentiated treatment option for TRD [13] - The company is also working on the final design for a late-stage clinical program in PTSD, indicating a significant commercial opportunity in this area due to high unmet needs [13] Other Important Information - The independent Data Safety Monitoring Board (DSMB) is regularly reviewing unblinded safety data, with a focus on suicidality, which remains a critical concern in the context of TRD [6][39] Q&A Session Summary Question: Key takeaways from the long-term follow-up data on durability and appropriate dosing - Management noted that while the data is not definitive, it suggests that patients receiving 25 mg can experience effects lasting up to six months, indicating this dose may be preferred moving forward [21] Question: Efficacy delta on MADRS and placebo effect considerations - Management acknowledged the variability in placebo effects in psychedelic trials and estimated a clinically significant effect size of over three on the MADRS scale [29] Question: Concerns regarding suicidality signals - Management clarified that suicidality is a core feature of depression and must be included in study designs, with ongoing monitoring to ensure safety [36] Question: Current delivery of esketamine by HealthPort - HealthPort has experience delivering SPRAVATO and is motivated to ensure access to new treatment options for underserved populations [42] Question: Manufacturing supply chain and FDA inspections - The company is currently manufacturing in the UK and plans to add US manufacturing capabilities, with multiple inspections conducted over the years [49] Question: Patient enrollment in COMM-five and comparison to Phase 2b - Management confirmed that recruitment criteria remain consistent, suggesting similar patient profiles across studies [55] Question: Interest in large pharma partnerships - The company is committed to commercializing COMM360 independently in the US, with no current plans for large pharma partnerships [58] Question: Optimal time frame for assessing suicidality risk post-treatment - Management indicated that predictions are difficult, and they will rely on data to inform their understanding of suicidality risk [61] Question: Changes in FDA interactions regarding psychedelic therapies - Management reported no significant changes in FDA interactions, maintaining routine discussions around event reporting [63]

本文来自微信公众号：家姻心理，作者：歌行，责编：张嘉仪，编辑：卢思伶，题图来自：《海边的曼 彻斯特》 "亲人的离去不是一场暴雨，而是此生漫长的潮湿。我将永远困在这潮湿中——是清晨空荡的厨房，是 晚归漆黑的窗。在每一个波澜不惊的日子里，掀起狂风骤雨。" 延长哀伤障碍，是指因亲近之人离世而引发的一种持续性哀伤反应。 这种反应超出了所在文化背景对哀伤的常规预期，并严重损害个体的日常生活和身心健康。 第一阶段：否认（Denial） "看到衣架上微皱的衬衫时，大脑会短暂地欺骗自己'他只是去买菜了'。这种自我保护的缓冲机制，正 是哀伤第一阶段在筑起柔软的防御墙。" 否认是大脑的自我保护机制，如同手术前的麻醉剂，为我们争取接受痛苦的时间。 个体往往通过隔离情感或忙碌行为逃避现实，为心灵筑起一道临时的"缓冲带"。 第二阶段：愤怒（Anger） "当超市货架上的饼干再次刺痛眼睛时，突然将手中的购物篮摔到一边。这种看似失控的暴怒，实则是 哀伤在试图冲破否认的茧房，用疼痛唤醒真实。" 心理学中的"哀伤五阶段"理论告诉我们，这些看似混乱无序的反应，其实是心灵自我修复的过程。 每一个阶段，都是我们向内和解、走向复原的尝试。 一、哀伤是 ...

现在，身边"有病"的人似乎越来越多，大家或多或少都有一些焦虑、抑郁的问题，宛平南路的上海精神病院一号 难求。据世界卫生组织（WHO）估计，在全球范围内每7名10-19岁的青少年中就有1人患有心理健康问题，包括 抑郁、焦虑、注意力缺陷多动障碍（ADHD）等。2022年我国首次开展全国规模的精神病流行病学调查显示：覆 盖五个省份的73992名6-16岁的青少年，儿童青少年整体精神障碍流行率为17.5%。 "双相""ADHD""BPD""CPTSD"等术语在社交媒体的讨论中变得逐渐流行。前不久，赵露思因"抑郁风波"成为焦 点，主持人齐思钧也公开了自己曾服用双相情感障碍药物的经历，越来越多公众人物开始承认自己的精神健康问 题。 当双相、抑郁、ADHD 成为这一代的共同语言，我们对这些问题真的了解吗？为什么年轻人在精神问题"症状 池"里打捞痛苦的解释？把疾病完全归因于社会结构，会有什么问题？借由新书《我脑袋里的小狐狸》的上市契 机，本期问题青年，我们和双相情感障碍的患者、精神科医生聊了聊。 我们都知道，有一种痛苦来自于痛苦被无视和否认，林奕含说，希望我们都成为"对她人的痛苦有更多想象力的 人"。 本期问题青年 陈陈｜青 ...